{"filing":{"accession_number":"0001104659-26-096417","cik":"0001346830","ticker":"TVRD","company_name":"Tvardi Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623143d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_8k.htm"},"events":[{"id":27719,"run_id":25295,"accession_number":"0001104659-26-096417","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses financial results including R\u0026D expenses ($4.0M vs $5.8M YoY), G\u0026A expenses ($2.6M vs $3.1M YoY), net loss ($6.5M vs net income of $4.2M in prior year), and EPS of $(0.69), along with consolidated balance sheets and statements of operations. The filing also includes material business updates on TTI-109 clinical progress and UC indication selection, which are integral to the earnings announcement.","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29373,"accession_number":"0001104659-26-096417","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses financial results including R\u0026D expenses ($4.0M vs $5.8M YoY), G\u0026A expenses ($2.6M vs $3.1M YoY), net loss ($6.5M vs net income of $4.2M in prior year), and EPS of $(0.69), along with consolidated balance sheets and statements of operations. The filing also includes material business updates on TTI-109 clinical progress and UC indication selection, which are integral to the earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:07:37.846703+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29373,"accession_number":"0001104659-26-096417","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses financial results including R\u0026D expenses ($4.0M vs $5.8M YoY), G\u0026A expenses ($2.6M vs $3.1M YoY), net loss ($6.5M vs net income of $4.2M in prior year), and EPS of $(0.69), along with consolidated balance sheets and statements of operations. The filing also includes material business updates on TTI-109 clinical progress and UC indication selection, which are integral to the earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:07:37.846703+00:00","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-08-14"}]}